KIES PETER 4

Accession 0001055726-24-000003

CIK 0001055726other

View on SEC.gov Company Profile

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 5:06 PM ET

Size

20.3 KB

Accession

0001055726-24-000003

Insider Transaction Report

Form 4

Period: 2024-02-26

INOVIO PHARMACEUTICALS, INC.INO

KIES PETER

CFO

Transactions

Exercise/Conversion
Common Stock
2024-02-26+3,997→ 24,516 total
Award
Restricted Stock Unit
2024-02-28+15,029→ 15,029 total
→ Common Stock (15,029 underlying)
Award
Common Stock Option
2024-02-28+18,750→ 18,750 total
Exercise: $8.46From: 2024-02-28Exp: 2034-02-28→ Common Stock (18,750 underlying)
Exercise/Conversion
Restricted Stock Unit
2024-02-26−1,878→ 0 total
→ Common Stock (1,878 underlying)
Exercise/Conversion
Restricted Stock Unit
2024-02-26−3,997→ 3,997 total
→ Common Stock (3,997 underlying)
Exercise/Conversion
Common Stock
2024-02-26+1,878→ 21,627 total
Tax Payment
Common Stock
2024-02-26$8.16/sh−2,358$19,241→ 22,158 total
Tax Payment
Common Stock
2024-02-26$8.16/sh−1,108$9,041→ 20,519 total

Holdings

Common Stock
(indirect: By Spouse)
375

Footnotes (7)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 5,635 restricted stock units was as follows: 1,879 shares vested on February 26, 2022; 1,878 shares vested on February 26, 2023; and 1,878 shares vested on February 26, 2024. Vested restricted stock units could be settled in shares of common stock, cash or a combination of both.
[F2]Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
[F3]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.
[F4]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 11,991 restricted stock units is as follows: 3,997 shares vested on February 26, 2023; 3,997 shares vested on February 26, 2024; and 3,997 shares will vest on February 26, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
[F5]The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (4) herein.
[F6]The vesting schedule for the 18,750 options is as follows: 4,688 shares vested on February 28, 2024; 4,688 shares will vest on February 28, 2025; 4,687 shares will vest on February 28, 2026; and 4,687 shares will vest on February 28, 2027.
[F7]Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 15,029 restricted stock units is as follows: 5,010 shares will vest on February 26, 2025; 5,010 shares will vest on February 26, 2026; and 5,009 shares will vest on February 26, 2027. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.

Documents

1 file

4
wk-form4_1709157959.xmlPrimary
FORM 4

Issuer

INOVIO PHARMACEUTICALS, INC.

CIK 0001055726

→

Entity typeother

Related Parties

filerCIK 0001259780

Filing Metadata

Form type: 4
Filed: Feb 27, 7:00 PM ET
Accepted: Feb 28, 5:06 PM ET
Size: 20.3 KB

View on SEC.gov